Miomira Vitezić
University of Rijeka
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Miomira Vitezić.
Value in Health | 2009
Dinko Vitezić; Tomislav Madjarevic; Tonči Buble; Branko Šestan; Miomira Vitezić; J. Mrsic Pelcic; G Zupan
The aim of this study was to detect changes in non-steroidal anti-inflammatory drugs (NSAIDs) financial expenditure and consumption according to the legal changes especially considering pricing policy (restrictive comparative pricing). Further, to analyze possible influences of new studies (connection between NSAIDs and increased cardiovascular risks) on NSAIDs utilization. The data was obtained from the Croatian National Health Insurance Institute and from pharmaceutical wholesalers for the seven-year period (2001-2007). Financial expenditure data are presented in Euros, while drug utilization data are presented in defined daily doses/1000 inhabitants/day (DDD/1000). In the investigated period the total expenditure of the group increased 10.39% while the related consumption of NSAID increased 1.95% (41.404 DDD/1000 to 42.224 DDD/1000). During the first part of the investigated period (from 2001-2005), before new pricing policy was introduced, the expenditure of NSAIDs increased 15.72% and the related consumption 5.92%. After the new measures were introduced (2005), in the period from 2005-2007 the financial expenditure of NSAIDs decreased 24.04% while usage decreased 4.03%. For the entire period diclofenac was the most frequently prescribed NSAID, but its share in the total consumption of NSAIDs decreased from 54.33 % in 2001 to 41.84% in 2007. The usage of NSAIDs in Croatia increased during the investigated period, so in 2005 new pricing policy was introduced to slow down the financial expenditure. This resulted in a considerable financial decrease and the usage was almost on the same level. The decrease of diclofenac usage in 2007 could be explained as the result of the published studies (the end of 2006) concerning its cardiovascular side effects.
principles and practice of constraint programming | 2012
Dinko Vitezić; Tomislav Madjarevic; Monja Gantumur; Tonči Buble; Miomira Vitezić; Miljenko Kovačević; Jasenka Mršić-Pelčić; Branko Šestan
Value in Health | 2011
Dinko Vitezić; M. Kucan; Miomira Vitezić; J. Mrsic Pelcic
Collegium Antropologicum | 2010
Dubravka Šepić-Grahovac; Dinko Vitezić; Nebojša Sindik; Miomira Vitezić; Tanja Grahovac
Value in Health | 2016
Dinko Vitezić; Davor Mance; Miomira Vitezić; J. Mrsic Pelcic
Value in Health | 2015
Dinko Vitezić; M. Kucan; J. Mrsic Pelcic; Miomira Vitezić
Second Croatian and First Adriatic Congress on Pharmacoeconomics and Outcomes Research with International Participation | 2011
Tomislav Mađarević; Dinko Vitezić; Marta Kučan; Monja Gantumur; Miomira Vitezić; Jasenka Mršić-Pelčić; Branko Šestan
Basic Clin Pharmacol Toxicol 2010 ; 107 (Suppl. 1): 431 | 2011
Tomislav Mađarević; Tonči Buble; Monja Gantumur; Miomira Vitezić; Branko Šestan; Jasenka Mršić Pelčić; Dinko Vitezić
Value in Health | 2010
Dinko Vitezić; M. Kucan; Miomira Vitezić; Miljenko Kovačević; J. Mrsic Pelcic
Abstracts of the 9th Congresss of the European Association for Clinical Pharmacology and Therapeutics, u: Basic & Clinical Pharmacology & Toxicology, Vol. 105, suppl. 1 | 2010
Tomislav Mađarević; Dinko Vitezić; Tonči Buble; Branko Šestan; Miomira Vitezić; Monja Gantumur; Jasenka Mršić-Pelčić; Gordana Župan